White Paper

Realizing The Commercial Promise Of Europe For Emerging Biopharma

By Markus Gores, Vice President, EMEA Thought Leadership, IQVIA; Tom Woods, Consultant, EMEA Thought Leadership, IQVIA; and Michele Cimmino, Director Sales and Account Management, IQVIA Biotech

GettyImages-1209427002 biopharm

In the realm of biomedical innovation, emerging biopharma companies (EBPs) have taken on an increasingly prominent role. In the past decade, these companies have embraced a new strategy of retaining ownership of their products and independently pursuing filing and commercialization.

While the U.S. market remains the primary focus for most EBPs, it is essential for them to broaden their horizons to maximize product value. Europe, as the second-largest pharmaceutical market globally, presents a compelling next step.

To take a closer look at the possibilities and challenges for EBPs looking to commercialize in Europe, the authors take a look at the crucial choices these companies must make to achieve success in this endeavor.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader